Mallinckrodt Inc

Mallinckrodt — Presentation (October 2020)

43 slides from Mallinckrodt's investor presentation, Oct 13, 2020

  1. Slide 1: October 2020 Discussion Materials

    October 2020 Discussion Materials Exhibit 99.2

  2. Slide 2: Table of Contents

    Table of Contents Section 1 Situation Update 2 Specialty Brands Business 3 Specialty Generics Business 4 Additional Company Detail 5 Restructuring Term Sheet Update 6 Overview of Intercompany Considerations

  3. Slide 3: 1. Situation Update

    SUBJECT TO FRE 408, STATE LAW EQUIVALENTS 1. Situation Update @) Mallinckrodt Pharmaceuticals

  4. Slide 4: Situation Overview

    Situation Overview While negotiating Balboa, the Company proactively executed multiple exchange offers that sought to deleverage the business and address near-term maturities December 2019 exchange of $706 million of unsecured notes into $323 million of 2L notes due 2025 April 2020 par exchange of $

  5. Slide 5: Situation Overview (cont'd)

    Situation Overview (cont’d) These operational, legal and balance sheet related challenges have increased the potential need for a restructuring through a chapter 11 of Mallinckrodt plc, guarantors under its funded debt and certain other subsidiaries (“WholeCo”) 2 1 3 Key Challenges Facing the Compan

  6. Slide 6: Litigation Environment

    Litigation Environment The recent decision by the U.S. Court of Appeals for D.C. to deny a temporary injunction against CMS will lead to $650 million of retroactive cash payments expected to be due in September or October 2020 Recently, the Company has reached a settlement in principle with CMS / DO

  7. Slide 7: Cash Flow Forecast vs. Near-Term Maturities

    ________________________ Projections are preliminary estimates. Unlevered free cash flow before cash taxes and after opioid settlement payments, opioid-related litigation expenses and restructuring execution costs. Illustratively represents current debt balances by maturity, excluding the impact of

  8. Slide 8: Mallinckrodt Pharmaceuticals: Managing complexity. Improving lives.

    Mallinckrodt Pharmaceuticals: Managing complexity. Improving lives. Company Overview: Branded pharmaceutical growth company with a separately-operated Specialty Generics segment capable of delivering solid cash flows focused on meeting the needs of underserved patients with severe and critical condi

  9. Slide 9: Mallinckrodt operates two scaled, profitable business segments

    Mallinckrodt operates two scaled, profitable business segments Specialty Brands Specialty Generics Product Mix(1) 2019 Net Sales(1) ~$2.4 billion ~$0.7 billion Strategic Focus Innovative branded drug development and commercialization Producing high-quality generic medicines in complex markets Strate

  10. Slide 10: 2. Specialty Brands Business

    2. Specialty Brands Business

  11. Slide 11: 2019 Net Sales: $2.4 billion

    2019 Net Sales: $2.4 billion Mallinckrodt’s commercial portfolio is comprised of diversified brands with strong clinical evidence and commercial performance 2019 Net Sales2 of Key In-Line Products ($B) Scaled branded pharmaceuticals platform with $2.4B net sales Diversified portfolio with Acthar <50

  12. Slide 12: Highly profitable Specialty Brands business built by commercial outperformance

    We have built a highly profitable Specialty Brands business by optimizing and driving commercial outperformance * Critical Care Product Net Sales: Fiscal Yr. Prior to Acquisition ($MM) Net Sales: 2019 ($MM) Absolute Growth CAGR Long-Term Strategy $761 (2013) $953 25% 4% Advance payor engagement and

  13. Slide 13: Innovation within the commercial portfolio to optimize revenue

    We continue to innovate within the commercial portfolio to optimize revenue generation for each franchise and extend life cycle New INOmax EVOLVE delivery device designed to improve operational efficiency and advance nitric oxide delivery in the hospital setting Clearly identifiable patients1 Linkag

  14. Slide 14: Robust late-stage pipeline aligned with therapeutic areas of focus

    Additionally, we have built a robust late-stage pipeline aligned with therapeutic areas of focus and existing commercial infrastructure New Product ________________________ Graft versus Host Disease. Hepatorenal Syndrome. Deep Partial Thickness. Full Thickness. Diabetic Foot Ulcers. Vascular Endothe

  15. Slide 15: Focus on underserved patients and scientific platforms

    Potential areas Neurology Nephrology Hepatology Rheumatology Primary criteria Secondary criteria Autoimmune / Immune Mediated Diseases (non-exhaustive) Critical care Underserved Patients Scientific Technology Platforms Acquire, license and develop platform technologies microbiome, NO1, ECP2, RNAi3 (

  16. Slide 16: Leading talent and capabilities to support strategic vision

    We have assembled leading talent and capabilities to support our strategic vision Key Capabilities Description Commercial (US and Int’l) Experienced and productive critical care and specialty salesforces with substantial reach and depth Comprehensive patient and account team enabling Total Care offe

  17. Slide 17: Specialty Brands business is multinational with over 1,800 employees

    Our Specialty Brands business is multinational with over 1,800 employees Administrative Offices Bedminster, NJ Hazelwood, MO Washington, DC Staines-Upon-Thames, UK Tokyo, Japan Mississauga, ON Canada Montreal, Canada Bonn, Germany Luxembourg Manufacturing Facilities Madison, WI Port Allen, LA Sanda,

  18. Slide 18: Opportunity to build a differentiated branded biopharma business

    Properly capitalized, Mallinckrodt has the opportunity to build a highly differentiated branded biopharma business Pure play biopharma innovator, with highly profitable product portfolio Strong cash flow generation to support growth Scaled commercial platform to drive growth and launch future brande

  19. Slide 19: 3. Specialty Generics Business

    3. Specialty Generics Business

  20. Slide 20: Differentiated U.S. Based Specialty Generics Business

    Differentiated U.S. Based Specialty Generics Business with Strong Leadership Position in Controlled Substances Worldwide and only remaining U.S. Acetaminophen(1) supplier ~1,600 Complex Generics Active Pharmaceutical Ingredients 2 Core Platforms Employees Share in addiction treatment clinics ~56% Wo

  21. Slide 21: Vertically Integrated, High Quality, U.S.-based Manufacturing Infrastructure

    Vertically Integrated, High Quality, U.S.-based Manufacturing Infrastructure Owned Leased Greenville, IL Compressible acetaminophen facility Webster Groves, MO Headquarters Commercial ready, R&D facility with pilot plant and R&D suites St. Louis, MO Multi-purpose API facility with manufacturing and

  22. Slide 22: Niche U.S.-based Specialty Generics Business

    Niche U.S.-based Specialty Generics Business with Leadership Position in Controlled Substances 2019 Net Sales by Product ($MM) KEY HIGHLIGHTS Generics Finish Dose Deep product portfolio in controlled substances ~30 product families (~20 in controlled substances) 150+ SKUs (~140 in controlled substan

  23. Slide 23: Leader in Niche Complex Generics Markets

    Leader in Niche Complex Generics Markets Key Highlights Broad, deep controlled substance portfolio Successful track record in: Product innovation (Concerta) Fast response to changing market conditions (hydrocodone combination product reclass) Established share of DEA quotas Well positioned for tight

  24. Slide 24: 4. Additional Company Detail

    4. Additional Company Detail

  25. Slide 25: Overview and Key Assumptions of Preliminary Consolidated Business Plan

    Overview and Key Assumptions of Preliminary Consolidated Business Plan Overview and Key Assumptions Overview Brands net sales decline in 2021 from Acthar pricing pressure, INOmax competition and Ofirmev loss of exclusivity INOmax sales moderately stabilized from EVOLVE device launch in 2021 Sales pl

  26. Slide 26: Preliminary Consolidated Business Plan

    ________________________ Source: MNK Preliminary Consolidated Business Plan as of June 2020. Note: Projections are preliminary estimates. Unlevered free cash flow before cash taxes, opioid settlement payments, opioid-related litigation expenses and restructuring execution costs. Unlevered free cash

  27. Slide 27: Overview of MNK Pipeline by Segment

    StrataGraft regenerative skin tissue is an investigational treatment being developed to reduce autograft in patients with severe thermal burns StrataGraft is also in Phase 3 clinical status and, if approved, is expected to launch in Q1 2021 with estimated exclusivity through 2032 StrataGraft assumes

  28. Slide 28: Illustrative Emergence Sources and Uses

    Illustrative Emergence Sources and Uses The following illustrative emergence sources and uses are based on an approximate 12-month bankruptcy filing commencing in August 2020 to implement the Company’s proposed restructuring plan Note that the Company expects an incremental ~$100 million of addition

  29. Slide 29: 5. Restructuring Term Sheet Update

    5. Restructuring Term Sheet Update

  30. Slide 30: Latest Framework

    Latest Framework(1) Credit Agreement Claims Reinstated at existing rates and maturities 1L Notes Reinstated at existing rates and maturities 2L Notes Reinstated at existing rates and maturities Unsecured Notes 100% of reorganized equity, prior to dilution from MIP and Opioid Plaintiff Warrants $375M

  31. Slide 31: Latest Framework: Opioid Plaintiffs

    Latest Framework(1) Opioid Plaintiffs $1.6BN of structured cash payments over 7 years, adjusted as follows: $450MM at emergence $200MM on each of the 1st and 2nd anniversaries of emergence $150MM on each of the 3rd through 7th anniversaries of emergence For 12-months post-emergence, ability to parti

  32. Slide 32: 6. Overview of Intercompany Considerations

    6. Overview of Intercompany Considerations

  33. Slide 33: Introduction

    Introduction Mallinckrodt plc and its subsidiaries operate a complex global business within an optimized multinational legal entity structure (the “Legal Entity Structure”) The Legal Entity Structure was developed to conduct business, control risks, and manage tax liabilities arising from the manufa

  34. Slide 34: Mallinckrodt Organizational Structure

    Mallinckrodt Organizational Structure ________________________ Note: This chart reflects the anticipated structure as of the projected filing date. Mallinckrodt plc (Ireland) Mallinckrodt UK Ltd (UK) Mallinckrodt Quincy Sarl (Luxembourg) Mallinckrodt Canada ULC (Canada) Mallinckrodt Group Sarl (Luxe

  35. Slide 35: Intercompany Overview

    Intercompany Overview Mallinckrodt engages in three types of intercompany activities which are summarized below and in additional detail on the following slides Intercompany Trade Includes the sale and purchase of goods between entities, payment for management & corporate services, royalties, resear

  36. Slide 36: Intercompany Trade Overview

    Intercompany Trade Overview Intercompany trade activities include the following types of transactions: Intercompany invoice flows: The Specialty Brands segment utilizes a limited risk distributor structure in which the Limited Risk Distributor (“LRD” or “LRDs”) entities market and distribute branded

  37. Slide 37: Intercompany Trade Overview (cont.)

    Intercompany Trade Overview (cont.) Royalties: Royalties, in consideration of the Intellectual Property used, are charged under a royalty license agreement between the licensor (“IP Licensor”) and licensee (“IP Licensee”) Research & Development (R&D): Various LRD entities engage in R&D projects and

  38. Slide 38: Intercompany Trade Matrix

    Counterparty Legal Entity Shared Services Entity 1 Generics Entity 1 Branded Entity 1 ARD 1 Branded Entity 2 Branded Entity 3 Parent 1 Branded Cash Pool Branded Entity 4 Branded Entity 5 Branded Entity 6 Other Total Shared Services Entity 1 – Plus – – – – Plus – (Minus) – – (Minus) Plus Generics Ent

  39. Slide 39: Simplified Intercompany Activity Flows

    Simplified Intercompany Activity Flows Overview The Specialty Brands segment utilizes an LRD structure under which the Manufacturer retains most of the economic value from manufacturing and distribution activities. The profits earned are used to pay a royalty to IP Licensor through a royalty license

  40. Slide 40: Intercompany CMA Overview

    Intercompany CMA Overview As a global operator, Mallinckrodt utilizes a centralized banking and cash management system which is largely maintained through four operating cash pools in the U.S. and in foreign jurisdictions. These cash pools engage in intercompany activity to facilitate global operati

  41. Slide 41: Summary of Cash Pools

    Summary of Cash Pools 2 The following table represents intercompany CMA balances by Pool Entity; balances are unaudited and are as of June 26, 2020 Positive values in the matrix represent balances owed to the entities on the top, from the entities on the left. Negative balances represent payables ow

  42. Slide 42: Intercompany Loan Overview

    Intercompany Loan Overview In addition to intercompany trade and CMA activity, the Company documents long-term intercompany loans, which originated primarily for the following reasons: Acquisition or financing activities (allocation of debt) Movement of Intellectual Property and other related activi

  43. Slide 43: Summary of Intercompany Loans

    Summary of Intercompany Loans 3 Summary of Branded Intercompany Loans(1) Borrower Brand / Gx Lender Brand / Gx Branded Entity 10 Brands Branded Entity 16 Brands Branded Entity 10 Brands Branded Entity 8 Brands IP Entity 1 Brands IP Entity Parent Brands IP Entity 2 Brands IP Entity Parent Brands IP E

Mallinckrodt — Presentation (October 2020) on 6ix